Table 4.

Metabolic Changes in Response to BPA and EE Exposure.

		Control	Bisphenol A					17α-Ethinyl Estradiol
		0.0 ppm	0.03 ppm	0.3 ppm	3.0 ppm	30 ppm	300 ppm	0.0001 ppm	0.001 ppm	0.01 ppm
Minimum sample size	F	5	6	8	9	6	8	10	10	8
	M	9	8	8	8	7	9	10	6	7
Triglycerides	F	138.4 ± 44.4	187.4 ± 23.6	155.3 ± 38.6	164.9 ± 36.4	164.6 ± 45.1	138.1 ± 34.4	121.1 ± 27.8	153.5 ± 43.7	153.9 ± 45.4
	M	108.4 ± 55.5	155.4 ± 68.5	131.5 ± 37.9	194.6 ± 36.3a	159.2 ± 60.8	148.0 ± 44.6	113.6 ± 66.4	162.2 ± 37.7	115.7 ± 35.7
Total cholesterol	F	136.7 ± 42.5	124.2 ± 33.2	123.9 ± 45.2	118.8 ± 26.0	139.0 ± 48.5	124.5 ± 25.1	121.9 ± 33.1	133.8 ± 26.1	144.9 ± 50.3
	M	144.1 ± 46.4	170.0 ± 35.8	146.4 ± 37.7	176.2 ± 27.8	189.7 ± 35.9a	175.6 ± 44.8	161.3 ± 27.5	187.7 ± 39.4a	165.0 ± 37.1
Phospholipids	F	194.4 ± 53.0	196.8 ± 42.0	178.9 ± 44.1	171.0 ± 25.1	213.3 ± 55.5	197.9 ± 36.8	173.3 ± 29.9	202.8 ± 47.2	224.1 ± 35.5
	M	210.9 ± 49.6	264.5 ± 52.6a	200.5 ± 21.7	238.1 ± 20.4	272.5 ± 41.6a	278.5 ± 48.6a	234.3 ± 46.3	295.2 ± 35.9a	268.1 ± 46.8
NEFA	F	1.5 ± 0.3	2.2 ± 0.5a	1.9 ± 0.3	2.0 ± 0.2	2.0 ± 0.4	1.8 ± 0.3	1.9 ± 0.4	1.8 ± 0.3	1.4 ± 0.3
	M	1.4 ± 0.5	1.9 ± 0.3a	1.8 ± 0.4a	1.9 ± 0.1a	1.8 ± 0.3a	1.7 ± 0.3	1.4 ± 0.4	1.6 ± 0.1	1.2 ± 0.3
% Body fat	F	12.0 ± 5.6	14.3 ± 3.4	13.8 ± 4.6	13.7 ± 5.7	15.9 ± 7.5	13.4 ± 4.4	13.5 ± 6.2	15.3 ± 5.0	13.8 ± 3.4
	M	10.4 ± 5.1	9.8 ± 2.4	16.1 ± 5.4	11.4 ± 5.3	12.0 ± 6.9	11.5 ± 2.1	12.8 ± 4.5	14.6 ± 5.3	8.9 ± 3.1
% Perigonadal fat	F	24.2 ± 5.6	28.5 ± 4.5	28.4 ± 8.4	21.4 ± 10.2	25.9 ± 10.3	29.0 ± 6.4	26.9 ± 4.7	21.6 ± 5.6	22.8 ± 5.9
	M	26.7 ± 11.6	28.6 ± 7.1	23.1 ± 10.3	13.5 ± 3.7a	17.3 ± 6.4	15.8 ± 2.7a	16.3 ± 4.4a	14.8 ± 2.3a	18.9 ± 4.6

Triglycerides, Total Cholesterol and Phospholipids measured in mg/dl; NEFA - non-esterified fatty acids (mEq/L).

% Body fat (g/g) = fat mass (from NMR; g) / Body wt (g) × 100.

% Perigonadal Fat (g/g) = perigonadal fat mass (g) / total body fat mass (from NMR; g) × 100.

^aSignificantly different from Control by ANOVA (p < 0.05) (n≥6 individuals).